ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2640

Prevalence and Predictors of ECG Cardiovascular Abnormalities in Lupus Patients

Zahi Touma1, Paula Harvey2, Dafna D. Gladman3, Dominique Ibanez1, Arthy Sabapathy3 and Murray B. Urowitz3, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Cardiology, Women's College Hospital, Toronto, ON, Canada, 3University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: cardiovascular disease and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Epidemiology, Women's Health, Cardiovascular and CNS

Session Type: Abstract Submissions (ACR)

Background/Purpose:   Patients with lupus are at increased risk for cardiovascular disease. Previous studies on healthy adults showed that abnormalities detected on resting electrocardiography (ECG) are associated with an increased risk for subsequent cardiovascular (CV) events. These ECG-CV abnormalities are: ST-segment and/or T-wave abnormalities, left ventricular hypertrophy (LVH), left-axis deviation and bundle branch block (BBB).

We aimed to determine the prevalence of ECG-CV abnormalities in a cohort of lupus patients and to examine the factors associated with ECG-CV abnormalities.

Methods:   A standard digitally recorded 12-lead resting supine ECG was performed on consecutive patients attending the Lupus Clinic between October 2012-May 2014. Coded ECGs were reviewed and interpreted by a cardiologist using the Minnesota code classification system.

The frequency of the ECG-CV abnormalities was determined. In the univariate analysis normal ECG and ECG-CV abnormalities were compared (T-test and chi-squared test). Covariates with p<0.1 in addition to age, sex and ethnicity were evaluated with a stepwise logistic regression model to predict the ECG-CV abnormalities.

Results:   461 patients were studied. Of the 461 resting ECGs, 39.5% were abnormal: 7.6% axis deviation, 3.5% atrial enlargement, 11.3% arrhythmia and 6.7% pathological Q waves. ECG-CV abnormalities were present in 120 patients and included: ST-segment abnormalities and/or T-wave abnormalities  in 17.4%, LVH in 8.9%, left-axis deviation in 4.1% and BBB in 6.3%.

Of the 120 patients with ECG-CV abnormalities, 65.0% had 1 abnormality, 26.7% had 2, 6.7% had 3 and 1.7% had all 4 abnormalities.

In the univariate analysis, in the group of ECG-CV abnormalities, patients were older, had a longer lupus duration, higher damage index, higher cumulative dose of corticosteroids, history of previous CAD event, presence of Coombs’, La, LE cells, SCL70 and anti phospholipid lupus antibodies (table 1).

In the multivariate analysis, older age (OR =1.03; 95% CI: 1.01, 1.05; p=0.002), presence of damage (OR= 1.33; 95% CI: 1.17, 1.52; p<0.0001) and positive Coombs' (OR=2.37; 95% CI: 1.34, 4.21; p=0.003) were associated with ECG-CV abnormalities.

Conclusion:   Of 461 resting ECGs 39.5% were abnormal. 26% had ECG-CV abnormalities. Older age, damage and Coombs’ test were associated with ECG-CV abnormalities. These patients are at higher risk of developing CV events.

 

Table 1. Comparison of normal ECG and ECG-CV abnormalities

  Normal ECG (n=279) ECG-CV abnormalities  (n=120) p
Sex        Female 91.0% 88.3% 0.40
Race    Caucasian Black Asian Other   57.0% 15.8% 11.5% 15.8%   60.0% 23.3% 7.5% 9.2%     0.08
Age   @ SLE Dx                      at visit closest ECG 30.3 ± 11.5 45.9 ± 13.0 30.6 ± 11.2 52.3 ± 14.8 0.84 <0.0001
Disease Duration @ ECG 15.6 ± 10.2 21.7 ± 12.5 <0.0001
SLEDAI-2K First available in clinic                       at visit closest ECG 9.2 ± 8.1 3.7 ± 4.3 9.1 ± 7.5 3.5 ± 4.3 0.87 0.75
SDI > 0         at visit closest ECG 60.4% 80.3% 0.0001
SDI               at visit closest ECG 1.29 ± 1.53 2.82 ± 2.62 <0.0001
SDI (Excluding Cardio) at visit closest ECG 1.24 ± 1.48 2.46 ± 2.39 <0.0001
Steroids   at visit closest ECG               Cumulative Dose at visit closest ECG (gr) 87.5% 33.8 ± 34.9 91.7% 61.3 ± 55.6 0.22 <0.0001
CAD         First available in clinic                  at visit closest ECG 0% 4.3% 1.7% 17.5% 0.09 <0.0001
Coombs  First available in clinic                 at visit closest ECG 32.2% 63.8% 40.7% 80.5% 0.11 0.001
LA           First available in clinic                 at visit closest ECG 18.3% 33.6% 22.2% 47.5% 0.44 0.009
LE           First available in clinic                                         at visit closest ECG 37.2% 58.1% 47.8% 73.0% 0.06 0.006
SCL70    First available in clinic                at visit closest ECG 7.7% 19.7% 11.7% 35.8% 0.28 0.0006
APLA    First available in clinic               at visit closest ECG 26.3% 50.4% 27.4% 61.3% 0.82 0.045

Other studied variables: AMS 3 years prior ECG, antimalarials and immunosuppressants ever @ ECG, Jo1, RNP, Ro, ANCA, anti dsDNA and ANA (p>0.05).

 


Disclosure:

Z. Touma,
None;

P. Harvey,
None;

D. D. Gladman,
None;

D. Ibanez,
None;

A. Sabapathy,
None;

M. B. Urowitz,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-and-predictors-of-ecg-cardiovascular-abnormalities-in-lupus-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology